Sensitivity of Human Leukemic Cells to Carvedilol
Authors
Abstract:
Background and Objective: Carvedilol, a non-specific β-blocker, has been used for treatment of hypertension, stroke and congestive heart failure. The therapeutic effects of β blockers in cancer patients have been shown. Carvedilol has considerable anti-inflammatory, anti-tumor and anti-angiogenic properties. In this study, the effects of carvedilol on proliferation of human U937 and Molt-4 leukemic cells were studied in vitro. Materials and Methods: Human leukemic T cells [Molt-4] and monocytes [U937] were cultured in Roswell Park Memorial Institute (RPMI) 1640 complete medium and were treated with different concentrations of carvedilol (1, 5, 10, 20, 50 and 100 μg/ml) for 24, 48 and 72 hours. The cytotoxicity of carvedilol on U937 and Molt-4 cells was determined using MTT (3-[4, 5 dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide) assay. Results: Carvedilol significantly decreased human U937 and Molt-4 leukemic cells proliferation, concentration- and time-dependently in comparison with control cells. Conclusion: According to our results, carvedilol has anti-proliferative effect on U937 and Molt-4 leukemic cells in a concentration- and time-dependent manner. Thus, carvedilol might be a useful candidate for treatment of leukemic patients as well as other cancers.
similar resources
Inhibition of Cyclin-dependent Kinase (CDK) Decreased Survival of NB4 Leukemic Cells: Proposing a p53-Independent Sensitivity of Leukemic Cells to Multi-CDKs Inhibitor AT7519
An unbounded number of events exist beneath the intricacy of each particular hematologic malignancy, prompting the tumor cells into an unrestrained proliferation and invasion. Aberrant expression of cyclin-dependent kinases (CDKs) is one of these events which disrupts regulation of cell cycle and subsequently, results in cancer progression. In this study, we surveyed the repressive impact of mu...
full textInhibition of Cyclin-dependent Kinase (CDK) Decreased Survival of NB4 Leukemic Cells: Proposing a p53-Independent Sensitivity of Leukemic Cells to Multi-CDKs Inhibitor AT7519
An unbounded number of events exist beneath the intricacy of each particular hematologic malignancy, prompting the tumor cells into an unrestrained proliferation and invasion. Aberrant expression of cyclin-dependent kinases (CDKs) is one of these events which disrupts regulation of cell cycle and subsequently, results in cancer progression. In this study, we surveyed the repressive impact of mu...
full textIncreased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine.
Tumor cell resistance to certain chemotherapeutic agents may result in cross-resistance to related antineoplastic agents. To study cross-resistance among inhibitors of ribonucleotide reductase, we developed hydroxyurea-resistant (HU-R) CCRF-CEM cells. These cells were 6-fold more resistant to hydroxyurea than the parent hydroxyurea-sensitive (HU-S) cell line and displayed an increase in the mRN...
full textSensitivity of leukemic human null lymphocytes to deoxynucleosides.
The growth of cultured leukemic T-lymphocytes is readily inhibited by deoxynucleosides, particularly thymidine, deoxyguanosine, and deoxyadenosine. By contrast, Epstein-Barr virus-transformed B-lymphocytes are relatively resistant to deoxynucleosides. Growth inhibition correlates with the development of high deoxyribonucleoside triphosphate pools following exposure to deoxynucleosides. Leukemic...
full textCuscuta campestris induces apoptosis by increasing reactive oxygen species generation in human leukemic cells
Objective: Cuscuta campestris or common dodder is a holoparasitic plant that has been valorized for treatment of liver injury and cancer prevention in traditional medicine. Recently, extract of C. campestris had shown moderate antimicrobial properties and cytotoxic effects. In this study, we examined the level of cellular oxidants, cytotoxicity, apoptosis and differentiation induced by hydr...
full textMy Resources
Journal title
volume 7 issue 1
pages 37- 42
publication date 2019-03-01
By following a journal you will be notified via email when a new issue of this journal is published.
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023